Salariuspharma
2 known investors
Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms conserved across multiple viruses. Its lead programs are inhaled, self-administered fusion inhibitors for respiratory viruses, including a pan-coronavirus treatment for immunocompromised patients and a combined flu/COVID/RSV antiviral.
Investors · 2
Frequently asked questions
- What does Salariuspharma do?
- Decoy Therapeutics is a biotechnology company developing Designable Multi-Antivirals (D-MAVs), peptide conjugate antivirals built on its AI-enabled IMP³ACT platform to target viral mechanisms conserved across multiple viruses. Its lead programs are inhaled, self-administered fusion inhibitors for respiratory viruses, including a pan-coronavirus treatment for immunocompromised patients and a combined flu/COVID/RSV antiviral.
- Who are Salariuspharma's investors?
- Salariuspharma's investors include Central Texas Angel Network, Dellin Investments.